191 related articles for article (PubMed ID: 31177166)
21. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
[TBL] [Abstract][Full Text] [Related]
22. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
23. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
J Cancer Res Clin Oncol; 2015 Mar; 141(3):495-503. PubMed ID: 25227457
[TBL] [Abstract][Full Text] [Related]
24. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
25. The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer.
Shiota M; Fujimoto N; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
J Urol; 2018 Mar; 199(3):734-740. PubMed ID: 28941922
[TBL] [Abstract][Full Text] [Related]
26. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
27. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
Anticancer Res; 2022 Feb; 42(2):1107-1114. PubMed ID: 35093913
[TBL] [Abstract][Full Text] [Related]
29. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
Shimodaira K; Nakashima J; Nakagami Y; Hirasawa Y; Hashimoto T; Satake N; Gondo T; Namiki K; Ohori M; Ohno Y
Urol J; 2020 Jan; 17(1):42-49. PubMed ID: 30882158
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
[TBL] [Abstract][Full Text] [Related]
32. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
33. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
34. Gleason score predicts androgen independent progression after androgen deprivation therapy.
Benaim EA; Pace CM; Roehrborn CG
Eur Urol; 2002 Jul; 42(1):12-7. PubMed ID: 12121723
[TBL] [Abstract][Full Text] [Related]
35. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
36. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
37. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
38. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.
Kato M; Tsuzuki T; Kimura K; Hirakawa A; Kinoshita F; Sassa N; Ishida R; Fukatsu A; Kimura T; Funahashi Y; Matsukawa Y; Hattori R; Gotoh M
Mod Pathol; 2016 Feb; 29(2):166-73. PubMed ID: 26743470
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
40. Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer.
Nieder C; Dalhaug A; Pawinski A
In Vivo; 2019; 33(2):465-468. PubMed ID: 30804126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
